| Literature DB >> 28544137 |
Lucas Robke1,2, Luca Laraia1, Marjorie A Carnero Corrales1,2, Georgios Konstantinidis3, Makoto Muroi4,5, André Richters2, Michael Winzker1,2, Tobias Engbring2, Stefano Tomassi2, Nobumoto Watanabe5,6, Hiroyuki Osada4,5, Daniel Rauh2, Herbert Waldmann1,2, Yao-Wen Wu3, Julian Engel2.
1. Max-Planck-Institute of Molecular Physiology, Department of Chemical Biology, Otto-Hahn-Strasse 11, 44227, Dortmund, Germany.
2. Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227, Dortmund, Germany.
3. Chemical Genomics Centre of the Max-Planck-Society, Otto-Hahn-Strasse 15, 44227, Dortmund, Germany.
4. Chemical Biology Research Group, RIKEN CSRS, 2-1, Hirosawa, Wako, Saitama, 351-0198, Japan.
5. RIKEN-Max Planck Joint Research Division for Systems Chemical Biology, RIKEN CSRS, 2-1, Hirosawa, Wako, Saitama, 351-0198, Japan.
6. Bio-Active Compounds Discovery Research Unit, RIKEN CSRS, 2-1, Hirosawa, Wako, Saitama, 351-0198, Japan.
Abstract
Entities:
Keywords: VPS34; aminopyrimidines; autophagy; kinase inhibitors; phenotypic assays
Mesh:
Autophagosomes/drug effects
Autophagy/drug effects
Class III Phosphatidylinositol 3-Kinases/antagonists & inhibitors
Drug Discovery
HEK293 Cells
HeLa Cells
Humans
MCF-7 Cells
Protein Kinase Inhibitors/chemistry
Protein Kinase Inhibitors/pharmacology
Pyrazoles/chemistry
Pyrazoles/pharmacology
Pyrimidines/chemistry
Pyrimidines/pharmacology
Sirolimus/pharmacology
Structure-Activity Relationship
Substances:
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
autophinib
Class III Phosphatidylinositol 3-Kinases
Sirolimus
Year: 2017 PMID: 28544137 DOI: 10.1002/anie.201703738
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336